Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Auer, M; Bsteh, G; Hegen, H; Wurth, S; Zinganell, A; Berger, T; Deisenhammer, F; Di Pauli, F.
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab
MULT SCLER RELAT DIS. 2020; 43: 102155
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Wurth Sebastian

Dimensions Citations:

Plum Analytics:
Ocrelizumab is a humanized monoclonal anti-CD20 antibody approved for treatment of relapsing-remitting and primary progressive multiple sclerosis (MS). Before approval of this drug, the chimeric anti-CD20 antibody rituximab was used off-label for treatment of MS. On treatment with rituximab late-onset neutropenia (LON) was reported as a rare adverse event. Here we report the case of a patient with MS who first received rituximab without experiencing any hematologic abnormalities, but developed grade IV LON after switching to ocrelizumab. This first case of LON in a patient treated with different anti-CD20 antibodies highlights the necessity of regular hemogram examinations during ocrelizumab.

Find related publications in this database (Keywords)
Adverse event
Multiple sclerosis
© Med Uni Graz Impressum